S&P 500
(0.02%) 5 071.63 points
Dow Jones
(-0.11%) 38 461 points
Nasdaq
(0.10%) 15 713 points
Oil
(0.10%) $82.89
Gas
(-0.18%) $1.650
Gold
(-0.54%) $2 325.80
Silver
(-0.77%) $27.14
Platinum
(-0.58%) $910.50
USD/EUR
(-0.06%) $0.934
USD/NOK
(-0.05%) $10.98
USD/GBP
(-0.01%) $0.802
USD/RUB
(0.00%) $92.32

Realtime updates for Nuformix PLC [NFX.L]

Exchange: LSE Industry: Pharmaceuticals, Biotechnology & Life Sciences
Last Updated24 Apr 2024 @ 09:05

-9.76% £ 0.185

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 09:05):

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care...

Stats
Today's Volume 2.93M
Average Volume 2.49M
Market Cap 1.68M
EPS £0 ( 2023-05-22 )
Next earnings date ( £0 ) 2024-06-29
Last Dividend £0 ( N/A )
Next Dividend £0 ( N/A )
P/E 0
ATR14 £0 (0.00%)

Nuformix PLC Correlation

10 Most Positive Correlations
10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nuformix PLC Financials

Annual 2023
Revenue: £0
Gross Profit: £-36 749.00 (0.00 %)
EPS: £-0.000800
Q2 2023
Revenue: £0
Gross Profit: £-18 343.00 (0.00 %)
EPS: £-0.000300
Q4 2022
Revenue: £0
Gross Profit: £-18 406.00 (0.00 %)
EPS: £-0.000500
Q2 2022
Revenue: £0
Gross Profit: £0 (0.00 %)
EPS: £-0.000600

Financial Reports:

No articles found.

Nuformix PLC

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators